Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q9BYZ2
UPID:
LDH6B_HUMAN
Alternative names:
-
Alternative UPACC:
Q9BYZ2; Q6DUY4; Q96LI2
Background:
L-lactate dehydrogenase A-like 6B, encoded by the gene with the UniProt accession number Q9BYZ2, plays a crucial role in cellular metabolism. This enzyme is involved in the conversion of lactate to pyruvate, an essential step in the anaerobic glycolytic pathway. Its activity is pivotal in tissues with high metabolic rates and in conditions where oxygen levels are limited.
Therapeutic significance:
Understanding the role of L-lactate dehydrogenase A-like 6B could open doors to potential therapeutic strategies. Its involvement in metabolic pathways suggests its potential as a target in metabolic disorders and diseases characterized by altered energy metabolism.